Immuneering Corporation (IMRX)
| Market Cap | 111.43M |
| Revenue (ttm) | 506,088 |
| Net Income (ttm) | -48.05M |
| Shares Out | 26.40M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 681 |
| Open | 4.14 |
| Previous Close | 4.19 |
| Day's Range | 4.14 - 4.22 |
| 52-Week Range | 3.74 - 16.17 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 17.75 (+320.62%) |
| Earnings Date | Mar 9, 2023 |
About IMRX
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Imm... [Read more]
Financial Performance
In 2021, Immuneering's revenue was $2.08 million, a decrease of -10.02% compared to the previous year's $2.31 million. Losses were -$33.54 million, 96.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $17.75, which is an increase of 320.62% from the latest price.
News
Immuneering To Present at Guggenheim 2023 Oncology Conference
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors ...
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint Blockade
Immuneering Announces Participation in November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...
Immuneering Appoints Leah R. Neufeld as Chief People Officer
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS m...
What Makes Immuneering Corporation (IMRX) a New Buy Stock
Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022 Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questiona...
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates ...
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade
The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...
Immuneering Announces Participation in September Investor Conferences
CAMBRIDGE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022
Why This Small-Cap Stock Is Gaining More Than 10% Today?
Chardan has initiated coverage of Immuneering Corp (NASDAQ: IMRX) with a Buy rating and a price target of $18. Immuneering's lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND ...
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022
CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...
Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer
Immuneering Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates d...
Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights
IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022
Immuneering Announces Participation in Citi's Biopharma VIRTUAL Co-Panel Day
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates de...
Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates ...